Document is current
Any future updates will be listed below
-
Authors
Zhou, Yanchen
Penny, Hweixian L
Kroenke, Mark A
Bautista, Bianca
Hainline, Kelly
Chea, Lynette S
Parnes, Jane
Mytych, Daniel T
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03075696 at ClinicalTrials.govnct03269136 at ClinicalTrials.govDocuments that mention this clinical trial
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
https://doi.org/10.1200/jco.23.02470
Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.
https://doi.org/10.1200/jco.2023.41.16_suppl.7550
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.
https://doi.org/10.1200/jco.2024.42.16_suppl.7008
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.
https://doi.org/10.1200/jco.2024.42.16_suppl.7020
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03145181 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20021
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01168-y
nct04557098 at ClinicalTrials.govDocuments that mention this clinical trial
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2024.42.16_suppl.7517
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8033
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8034
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8011
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2024.42.16_suppl.7540
nct03933735 at ClinicalTrials.govDocuments that mention this clinical trial
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2024.42.16_suppl.7517
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8033
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8034
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8011
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2024.42.16_suppl.7540
nct03399799 at ClinicalTrials.govDocuments that mention this clinical trial
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2024.42.16_suppl.7532
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1200/jco.22.01504
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2024.42.16_suppl.7531
nct01221571 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8041
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2025-013986
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8036
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8020
nct02665650 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct01221571 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02665650 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03330561 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct01688206 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02141295 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct01688206 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02141295 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct02298387 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03030287 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02298387 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03030287 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03752177 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03440437 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
https://doi.org/10.1136/jitc-2021-003679
nct03030287 at ClinicalTrials.govDocuments that mention this clinical trial
395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy
https://doi.org/10.1136/jitc-2020-sitc2020.0395
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
715 FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action
https://doi.org/10.1136/jitc-2020-sitc2020.0715
Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report
https://doi.org/10.1136/jitc-2022-005225
nct03752177 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct01471210 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
https://doi.org/10.1136/jitc-2021-003679
nct01307267 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02179918 at ClinicalTrials.govDocuments that mention this clinical trial
Role of Fcγ receptors in HER2-targeted breast cancer therapy
https://doi.org/10.1136/jitc-2021-003171
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
https://doi.org/10.1136/jitc-2019-000238
nct02444793 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Rationale for anti-CD137 cancer immunotherapy
https://doi.org/10.1016/j.ejca.2015.09.026
nct03330561 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct01723475 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct03926013 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
nct02262910 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Documents that mention this clinical trial
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
- License Information
